PTO/SB/08B (08-00)
Please type a plus sign (+) inside this box + Approved for use through 10/31/2002. OMB 085 00031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COmpress U.S. Department of Compress Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control pumber.

				C mplete if Known			
Substitute for form 1449B/PTO				Application Number	09/982,351	田田	n
INFO	ORMATIC	NC	DISCLOSURE	Filing Date	October 18, 2001	D	و
STATEMENT BY APPLICANT				First Named Inventor	Aleem Gangjee	<u></u> 5	
				Group Art Unit	1615	<u> </u>	
	luse as man	ıv she	ets as necessary)	Examiner Name		-183	
Sheet	1	0		Attorney Docket Number	049450-00170	<u>8</u>	_/

E								
(6 = 20)	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
7 8 2002 4	Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
ATENT & TRADERS	M3	Α	CHERRINGTON ET AL., "New Paradigms for the Treatment of Cancer: The Role of Anti-Angiogenesis Agents", Advances in Cancer Research, 2000, pp. 1-38					
·	10)	В	TRAXLER ET AL., "Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors", Pharmacol. Ther. Vol. 82, Nos. 2-3, pp. 195-206, 1999					
ORIGINAL TRILE	AND	С	SUN ET AL., "Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinae inhibitors", Reviews, DDT Vol. 5 No. 8 August 2000, pp. 344-353					
CORTCHALL	<u>'</u>							
			RECEIVED					
			MAR - 4 2002					
		-	TECH CENTER 1600/290	b-				
•								
•								
•		-						
	:							
•		<u> </u>		+				

Examiner	Mark Beel	Date Considered	7-11-02
Signature	Man Day		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.